Quintiles invests in cancer biomarker start-up
This article was originally published in Clinica
Executive Summary
Quintiles has invested £3m ($4.7m) in a new company formed in partnership with the University of Oxford and two of its professors, which will provide oncology consulting services and new cancer biomarkers to clients for personalised medicine applications.